Neuroscience Research Institute
Clinical Trials
: BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease (Brainshuttle AD)
This study is currently enrolling.
Trontinemab is an experimental drug that is being developed for the possible treatment of AD. Trontinemab combines an anti-amyloid antibody with a brain shuttle module which helps to deliver the antibody to the brain. It works ...
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
This study is currently enrolling.
The purpose of this open label study is to assess the safety, tolerability, and effects of LY3884963 on plasma (the liquid component of blood) and/or cerebrospinal fluid (CSF; fluid from the area surrounding the brain) PGRN lev ...
A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE
This study is currently enrolling.
The purpose of this study is to investigate what happens to RO7486967 once it is in the body, what RO7486967 does to the body, and to compare the effects (good or bad) of RO7486967 versus placebo on the inflammation in the brai ...
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
This study is currently enrolling.
We are conducting this research study to find out if study drug GSK4527226 [AL101], a drug being developed by GSK together with another company called Alector, can reduce the loss of memory and decline in daily functioning usua ...
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy
This study is currently enrolling.
This is a research study to test a new investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The main purpose of this study is to assess whether an in ...
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is currently enrolling.
The purpose of this study is to see if batoclimab is safe and helps people with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disorder. Batoclimab is also known as IMVT-1401 (and was previously referre ...
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease
This study is currently enrolling.
You may be eligible to take part in the study because you have Parkinson’s Disease (PD). Only people who have been diagnosed with PD in the past 2 years and who are within the ages of 30 to 80 years can take part in the study. ...
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
This study is currently enrolling.
The purpose of this study is to see if an experimental drug, called Milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient isc ...
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
This study is currently enrolling.
The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer MS relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known ...